Clinical trials
C3 Glomerulopathy clinical trials
Below are recruiting c3 glomerulopathy clinical trials, each written for real people, not researchers. We’re tracking 10 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07483827RecruitingPhase 1
Testing CPV-104 safety in healthy people and C3G patients
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
ViennaAges 18 years+ - NCT04183101RecruitingPhase 2
Aliskiren vs enalapril for C3 kidney inflammation
This trial tests whether aliskiren works better or as well as enalapril to treat C3 glomerulopathy/dense deposit disease confirmed by a kidney biopsy. It may help by improving kidney outcomes in people with this specific kidney condition.
GothenburgAges 6 years+ - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT07416162Recruiting
Study of iptacopan for PNH or C3G in Korea
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
JeollanamAges 18–99 - NCT06209736RecruitingPhase 2
Study of OMS906 for C3G and ICGN kidney diseases
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
KaunasAges 18–99 - NCT07029542Recruiting
Home reporting in C3G: a study for patients and caregivers
This study uses a smartphone app to track health information from people with C3G (a rare kidney disease) and their caregivers. It aims to collect real-world data to better understand the condition, no matter what treatments you are on.
East Hanover, New JerseyAges 18–100 - NCT07746895RecruitingPhase 4
Study of pegcetacoplan for C3G or IC-MPGN kidney disease
This study looks at how well pegcetacoplan works and how safe it is for people with two rare kidney diseases, called C3G and IC-MPGN. It will help doctors understand how the medicine helps patients in real life, outside of a strict clinical trial.
KingswoodAges Any age - NCT03955445RecruitingPhase 3
Study for long-term iptacopan in C3G or IC-MPGN
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
Aurora, ColoradoAges 12–100 - NCT04817618RecruitingPhase 3
Iptacopan for kidney inflammation in C3 glomerulopathy
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
Aurora, ColoradoAges 12–60 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for c3 glomerulopathy?
- Yes. Clin2 currently lists 10 recruiting c3 glomerulopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a c3 glomerulopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a c3 glomerulopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.